Search results
Results from the WOW.Com Content Network
Bronchospasm or a bronchial spasm is a sudden constriction of the muscles in the walls of the bronchioles. It is caused by the release ( degranulation ) of substances from mast cells or basophils under the influence of anaphylatoxins .
Bronchospasm: Withdrawn due to Bronchospasm risk Mivacurium (Mivacron) 90 12–18 [13] hypotension (transiently), by release of histamine [13] No longer manufactured secondary to marketing, manufacturing, and financial concerns refrigerated Atracurium (Tracrium) 90 30 min or less [13] hypotension, transiently, [13] by release of histamine
Bronchial hyperresponsiveness (or other combinations with airway or hyperreactivity, BH used as a general abbreviation) [1] is a state characterised by easily triggered bronchospasm (contraction of the bronchioles or small airways). Bronchial hyperresponsiveness can be assessed with a bronchial challenge test.
Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by chronic respiratory symptoms and airflow limitation. [8] GOLD 2024 defined COPD as a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea or shortness of breath, cough, sputum production or exacerbations) due to abnormalities of the airways (bronchitis ...
In April 2020, the FDA approved the first generic of Proventil HFA (albuterol sulfate) metered dose inhaler, 90 μg per inhalation, for the treatment or prevention of bronchospasm in patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group. [35]
Inflamed airways are more hyper-reactive, and will be more prone to bronchospasm. The "hygiene hypothesis" postulates that in early life, an imbalance in the regulation of these T H cell types leads to a long-term domination of the cells involved in allergic responses over those involved in fighting infection.
For maintenance treatment, once every four weeks dosing regimen may be easier than once every two weeks dosing for patients and care partners to continue treatment for early AD. Ongoing treatment can slow disease progression and prolong the benefit of therapy, 4 with the goal of helping patients maintain who they are for longer.
Lower airway: may occur from bronchospasm, drowning, or airspace filling disorders (e.g. pneumonia, pulmonary edema, pulmonary hemorrhage). [7] Obstructive conditions of the lower airway, including severe asthma or COPD episodes, can also lead to respiratory arrest. During these episodes, known as exacerbations, airway resistance is increased ...